In this episode, the third of a three-part series, John B. Pinto discusses some of the future megatrends expected for ophthalmic practices, challenge practices may face in the future, and more.

• Intro :13
• What you think the megatrends are going to be over the next decade or so in the ophthalmic practices :50
• What do you think is the most important topic or issue or challenge facing ophthalmic practices now and in the future? 4:46
• If our listeners wanted to learn more, what’s the best way to contact you? 10:02
• I really appreciate you and all your great advice 10:47
• Any final words? 11:00
• Thank you so much John, I appreciate it 11:16

John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership.

UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20.

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.